Skip to main content
. 2014 Jan 17;53(5):904–913. doi: 10.1093/rheumatology/ket465

Fig. 1.

Fig. 1

Patient disposition through week 52.

aPPS. One patient randomized to ADA + MTX received two doses of study drug at baseline and was excluded from this analysis. bThree patients in the ADA + MTX group and one in the PBO + MTX group discontinued from the study at week 26. ADA: adalimumab; PBO: placebo.